220 related articles for article (PubMed ID: 25298577)
21. Reduced basal ganglia volumes after switching to olanzapine in chronically treated patients with schizophrenia.
Lang DJ; Kopala LC; Vandorpe RA; Rui Q; Smith GN; Goghari VM; Lapointe JS; Honer WG
Am J Psychiatry; 2004 Oct; 161(10):1829-36. PubMed ID: 15465980
[TBL] [Abstract][Full Text] [Related]
22. Risperidone versus olanzapine for schizophrenia.
Jayaram MB; Hosalli P; Stroup S
Cochrane Database Syst Rev; 2006 Apr; (2):CD005237. PubMed ID: 16625629
[TBL] [Abstract][Full Text] [Related]
23. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study.
Sikich L; Frazier JA; McClellan J; Findling RL; Vitiello B; Ritz L; Ambler D; Puglia M; Maloney AE; Michael E; De Jong S; Slifka K; Noyes N; Hlastala S; Pierson L; McNamara NK; Delporto-Bedoya D; Anderson R; Hamer RM; Lieberman JA
Am J Psychiatry; 2008 Nov; 165(11):1420-31. PubMed ID: 18794207
[TBL] [Abstract][Full Text] [Related]
24. Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial.
Lublin H; Haug HJ; Koponen H; Sigmundsson T; Kolb SA
World J Biol Psychiatry; 2009; 10(4 Pt 3):710-8. PubMed ID: 18803070
[TBL] [Abstract][Full Text] [Related]
25. Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study.
Smith RC; Lindenmayer JP; Hu Q; Kelly E; Viviano TF; Cornwell J; Vaidhyanathaswamy S; Marcovina S; Davis JM
Schizophr Res; 2010 Jul; 120(1-3):204-9. PubMed ID: 20457512
[TBL] [Abstract][Full Text] [Related]
26. A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia.
Chan HY; Chiang SC; Chang CJ; Gau SS; Chen JJ; Chen CH; Hwu HG; Lai MS
J Clin Psychiatry; 2010 Sep; 71(9):1226-33. PubMed ID: 20441726
[TBL] [Abstract][Full Text] [Related]
27. Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO study.
Haro JM; Novick D; Suarez D; Roca M
J Psychiatr Res; 2009 Jan; 43(3):265-73. PubMed ID: 18644606
[TBL] [Abstract][Full Text] [Related]
28. A comparison of the efficacy and safety of olanzapine and risperidone in the treatment of elderly patients with schizophrenia: an open study of six months duration.
Ritchie CW; Chiu E; Harrigan S; MacFarlane S; Mastwyk M; Halliday G; Hustig H; Hall K; Hassett A; O'Connor DW; Opie J; Nagalingam V; Snowdon J; Ames D
Int J Geriatr Psychiatry; 2006 Feb; 21(2):171-9. PubMed ID: 16416458
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
[TBL] [Abstract][Full Text] [Related]
30. A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone.
Perez-Iglesias R; Crespo-Facorro B; Amado JA; Garcia-Unzueta MT; Ramirez-Bonilla ML; Gonzalez-Blanch C; Martinez-Garcia O; Vazquez-Barquero JL
J Clin Psychiatry; 2007 Nov; 68(11):1733-40. PubMed ID: 18052567
[TBL] [Abstract][Full Text] [Related]
31. Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis.
Czekalla J; Beasley CM; Dellva MA; Berg PH; Grundy S
J Clin Psychiatry; 2001 Mar; 62(3):191-8. PubMed ID: 11305706
[TBL] [Abstract][Full Text] [Related]
32. Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study.
Meyer JM; Pandina G; Bossie CA; Turkoz I; Greenspan A
Clin Ther; 2005 Dec; 27(12):1930-41. PubMed ID: 16507379
[TBL] [Abstract][Full Text] [Related]
33. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.
Dossenbach M; Arango-Dávila C; Silva Ibarra H; Landa E; Aguilar J; Caro O; Leadbetter J; Assunção S
J Clin Psychiatry; 2005 Aug; 66(8):1021-30. PubMed ID: 16086618
[TBL] [Abstract][Full Text] [Related]
34. Obsessive-compulsive symptoms in patients with schizophrenia: a naturalistic cross-sectional study comparing treatment with clozapine, olanzapine, risperidone, and no antipsychotics in 543 patients.
Scheltema Beduin AA; Swets M; Machielsen M; Korver N;
J Clin Psychiatry; 2012 Nov; 73(11):1395-402. PubMed ID: 23218156
[TBL] [Abstract][Full Text] [Related]
35. Longitudinal effect of olanzapine on fasting serum lipids: a randomized, prospective, 4-month study.
Kinon BJ; Liu-Seifert H; Ahl J; Ahmed S; Baker RW
Ann N Y Acad Sci; 2004 Dec; 1032():295-6. PubMed ID: 15677433
[TBL] [Abstract][Full Text] [Related]
36. Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients.
Melkersson K
J Clin Psychiatry; 2005 Jun; 66(6):761-7. PubMed ID: 15960571
[TBL] [Abstract][Full Text] [Related]
37. Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study.
Saddichha S; Manjunatha N; Ameen S; Akhtar S
J Clin Psychiatry; 2007 Nov; 68(11):1793-8. PubMed ID: 18052574
[TBL] [Abstract][Full Text] [Related]
38. Differential effects of olanzapine and risperidone on plasma adiponectin levels over time: results from a 3-month prospective open-label study.
Wampers M; Hanssens L; van Winkel R; Heald A; Collette J; Peuskens J; Reginster JY; Scheen A; De Hert M
Eur Neuropsychopharmacol; 2012 Jan; 22(1):17-26. PubMed ID: 21511441
[TBL] [Abstract][Full Text] [Related]
39. A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia.
Adams DH; Kinon BJ; Baygani S; Millen BA; Velona I; Kollack-Walker S; Walling DP
BMC Psychiatry; 2013 May; 13():143. PubMed ID: 23694720
[TBL] [Abstract][Full Text] [Related]
40. Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol.
Volavka J; Czobor P; Cooper TB; Sheitman B; Lindenmayer JP; Citrome L; McEvoy JP; Lieberman JA
J Clin Psychiatry; 2004 Jan; 65(1):57-61. PubMed ID: 14744169
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
